NCT04374526View on ClinicalTrials.gov

Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

May 27, 2020

Primary Completion Date

May 26, 2021

Study Completion Date

May 26, 2021

Conditions
Coronavirus Disease 2019 )COVID-19)
Interventions
BIOLOGICAL

COVID-19 Convalescent Plasma

ABO matched pathogen-inactivated CCP is transfused at a dose of 200 ml/day for 3 days (days 1, 2, and 3).

Trial Locations (3)

66100

Ospedale SS Annunziata, Chieti

00168

Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma

00149

Istituto Nazionale Malattie Infettive Lazzaro Spallanzani, Rome

All Listed Sponsors
lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

NCT04374526 - Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression. | Biotech Hunter | Biotech Hunter